Avalo Therapeutics, Inc.
AVTX· Nasdaq
Released Mar 8, 2021, after the close
10-K filed Mar 8, 2021, 67 days after period end · 0001628280-21-004162
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017 |
|---|---|---|---|---|
| Revenue | $1.50M | $580.81K | — | $1.91M |
| Net Income | -$15.64M | $1.62M |
Avalo Therapeutics, Inc. · CIK 1534120 · Engraved from SEC EDGAR
| -$5.56M |
| -$3.09M |
| EPS Diluted | — | — | — | -$0.11 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.